BioCryst Pharmaceuticals Inc
$ 9.67
2.76%
14 Apr - close price
- Market Cap 2,360,034,000 USD
- Current Price $ 9.67
- High / Low $ 9.68 / 9.37
- Stock P/E 7.78
- Book Value -0.56
- EPS 1.21
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.43 %
- ROE -19.25 %
- 52 Week High 11.31
- 52 Week Low 6.00
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$21.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-11-04 | 2024-08-05 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 1.1212 | 0.16 | 0.02 | 0.0001 | -0.13 | -0.07 | -0.06 | -0.17 | -0.28 | -0.19 | -0.24 | -0.28 |
| Estimated EPS | 0.0344 | 0.05 | 0.01 | -0.21 | -0.0604 | -0.06 | -0.17 | -0.21 | -0.24 | -0.23 | -0.23 | -0.3 |
| Surprise | 1.0868 | 0.11 | 0.01 | 0.2101 | -0.0696 | -0.01 | 0.11 | 0.04 | -0.04 | 0.04 | -0.01 | 0.02 |
| Surprise Percentage | 3159.3023% | 220% | 100% | 100.0476% | -115.2318% | -16.6667% | 64.7059% | 19.0476% | -16.6667% | 17.3913% | -4.3478% | 6.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCRX
2026-04-14 12:39:16
This article discusses precision trading strategies for Biocryst Pharmaceuticals Inc. (BCRX) based on AI-generated signals. It outlines a detailed analysis of near-term sentiment, price positioning, and potential downside risks, offering three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop loss points. The analysis also includes multi-timeframe signal strengths and support/resistance levels for BCRX.
2026-04-13 04:08:55
BioCryst Pharmaceuticals Inc (BCRX.O) is currently considered undervalued, with a fair price estimated between $29522.33 to $29543.81 compared to its current price of $9.56. While its forward PS ratio of 3.39 is deemed undervalued against its five-year average, some other metrics like its P/B ratio and FCF yield suggest mixed valuation signals when compared to historical and industry averages. The article provides detailed valuation metrics such as P/E, P/S, EV/EBITDA, and FCF yield, alongside explanations of these figures as of April 13, 2026.
2026-04-13 04:08:55
The article provides a technical analysis and stock price forecast for BioCryst Pharmaceuticals Inc (BCRX), indicating a "Strong Buy" overall consensus based on various technical indicators. It details the readings of momentum indicators like RSI and MACD, as well as support, resistance levels, and moving averages. The analysis suggests that BCRX is currently trading above its key moving averages, reinforcing a positive outlook.
2026-04-12 10:39:35
This page from TradingView provides financial information specifically focusing on the free cash flow per share for BioCryst Pharmaceuticals, Inc. (DUS:BO1). It indicates the market was closed at the time of viewing and includes copyright and data source acknowledgments for FactSet and American Bankers Association. The primary content available is a table showing the period, value, and percentage change for free cash flow per share.
2026-04-12 04:39:02
BioCryst Pharmaceuticals Inc (BCRX) is currently considered undervalued, with its forward PS ratio of 3.39 being significantly lower than its five-year average. According to a relative valuation method, the fair price of BCRX is estimated to be between 29522.34 and 29543.84, indicating it is undervalued by 99.97% compared to its current price of 9.56 USD. Despite its high P/S ratio compared to competitors, its robust revenue growth of 209.09% suggests this premium might be sustainable.
2026-04-10 12:10:18
This article provides an overview of BIOCRYST PHARMACEUTICALS INC (BCRX) stock, including its current price, performance metrics, and key statistics. It also details ChartMill's technical and fundamental analysis ratings, earnings information, and analyst forecasts. The company profile highlights its marketed products and pipeline candidates.
